🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Australia to receive first batch of AstraZeneca COVID-19 vaccine in January 2021 - PM to say

Published 2020-09-06, 08:34 a/m
© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

By Colin Packham

SYDNEY (Reuters) - Australia will receive the first doses of an AstraZeneca and Oxford University COVID-19 vaccine in January 2021 if trials prove successful, after Canberra agreed a deal to purchase a second potential vaccine, Prime Minister Scott Morrison will say on Monday.

Australia said in August it had signed a preliminary agreement with AstraZeneca for enough doses for its population of nearly 26 million, which would be manufactured locally by pharmaceutical company CSL.

That deal appeared in some doubt when CSL said its priority was manufacturing an alternative potential vaccine developed with the University of Queensland (UQ).

Agreeing a deal to overcome the potential roadblock, Australia will now also buy 51 million doses of the UQ vaccine.

It will take possession of the first 3.8 million doses of the AstraZeneca vaccine in January and February 2021, and then receive a further 30 million doses, Morrison will say in extracts from an announcement sent to Reuters.

AstraZeneca’s candidate is seen as a frontrunner in a global race to deliver an effective coronavirus vaccine.

"Australians will be among the first in the world to receive a safe and effective vaccine, should it pass late stage testing," Morrison will say.

Under the deal with UQ and CSL, Australia will buy 51 million doses of that tie-up's vaccine. The UQ and CSL candidate is scheduled to begin phase two trials in late 2020 and if all trials are successful it could be rolled out to Australians in mid-2021.

Both deals will cost in total A$1.7 billion ($1.24 billion), Morrison will say. Should both vaccines prove successful, Australia has secured to right to donate or sell on without a mark-up.

Health officials are discussing who will receive the first doses if trials are successful, Morrison will say. Vulnerable people, and front-line health care workers likely to be first in line, a source familiar with the details told Reuters.

The supply agreements come as Australia grapples with a second wave of infections in its second most populous state, Victoria. Australia has recorded more than 26,000 infections and 753 deaths.

© Reuters. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

(This story corrects to show announcement will be made on Monday not Tuesday)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.